SCHEMBL5234944

SCHEMBL5234944

CCN1C(=O)CCNc2ccccc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRPF1 P55201 1/20 0.50
BRD4 O60885 1/20 0.43
ATAD2 Q6PL18 1/20 0.41
CYP1A2 P05177 1/20 0.39
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
CHRM2 P08172 1/20 0.39
CHRM4 P08173 1/20 0.39
CHRM5 P08912 1/20 0.39
CHRM1 P11229 1/20 0.39
DRD2 P14416 1/20 0.39
CHRM3 P20309 1/20 0.39
DRD4 P21917 1/20 0.39
DRD3 P35462 1/20 0.39
ALOX5 P09917 1/20 0.38
LMNA P02545 3/20 0.37
ADORA3 P0DMS8 1/20 0.37
HSD17B3 P37058 1/20 0.37
ALDH1A1 P00352 2/20 0.36
ALPL P05186 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11493458 0.85 CHRM2 (0.50) BRPF1CHRM2CHRM4CHRM5CHRM1
SCHEMBL22122379 0.80 ATAD2 (0.44) BRD4ATAD2CYP1A2CYP11B1CYP11B2
SCHEMBL5025475 0.80 MEN1 (0.53) BRPF1ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL2625081 0.80 ATAD2 (0.41) BRPF1BRD4ATAD2CYP1A2CYP11B1
SCHEMBL6971065 0.80 NPSR1 (0.56) LMNAALDH1A1SMN1; SMN2GSK3BGSK3A
SCHEMBL5230478 0.78 BRPF1 (0.69) BRPF1BRD4CYP1A2CYP11B1CYP11B2
SCHEMBL31033153 0.77 ALDH1A1 (0.50) BRPF1CHRM2CHRM4CHRM5CHRM1
SCHEMBL2628423 0.76 PARP10 (0.42) ATAD2CYP1A2CYP11B1CYP11B2ALDH1A1
SCHEMBL11455051 0.74 BRPF1 (0.63) BRPF1BRD4CHRM2CHRM4CHRM5
SCHEMBL1239067 0.74 KMT2A (0.53) BRPF1DRD2DRD4DRD3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1294698-B1 FUSED AZEPINE DERIVATIVES AND THEIR USE AS ANTIDIURETIC AGENTS FERRING BV (NL) 2007-08-01 EP disclosed
US-7176195-B2 Fused azepine derivatives and their use as antidiuretic agents FERRING BV (NL) 2007-02-13 US disclosed
US-20040038962-A1 Fused azepine derivatives and their use as antidiuretic agents VANTIA LIMITED (GB) 2004-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038962-A1 Fused azepine derivatives and their use as antidiuretic agents AVPR2, AVPR1A, AVPR1B BRPF1 2964/4885BRD4 3181/4885ATAD2 1072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.